WEN-JEN HWU to Fatigue
This is a "connection" page, showing publications WEN-JEN HWU has written about Fatigue.
Connection Strength
0.179
-
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. J Immunother. 2017 Nov/Dec; 40(9):334-340.
Score: 0.098
-
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018 02 22; 3(4).
Score: 0.025
-
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17.
Score: 0.020
-
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res. 2009 Aug; 19(4):238-42.
Score: 0.014
-
Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol. 1996 Apr; 19(2):149-53.
Score: 0.011
-
Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol. 1996 Apr; 19(2):187-9.
Score: 0.011